PMID- 26255950
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20190918
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 16
IP  - 13
DP  - 2015
TI  - Therapeutic potential of alpha-glucosidase inhibitors in type 2 diabetes mellitus: an 
      evidence-based review.
PG  - 1959-81
AB  - INTRODUCTION: Postprandial hyperglycemia (PPHG) contributes to micro- and 
      macro-vascular complications more than fasting hyperglycemia in patients with 
      type 2 diabetes mellitus. Due to the traditional carbohydrate-rich diet, Asians, 
      particularly Indians and Chinese need agents to control the higher risk of 
      uncontrolled PPHG. Targeting PPHG with alpha-glucosidase inhibitors (AGIs), either 
      alone or in combination with other oral hypoglycemic agents and insulin, provide 
      overall glycemic control with transient mild gastrointestinal disorders. 
      Treatment with AGIs, especially acarbose, has also shown to provide beneficial 
      effects on lipid levels, blood pressure, coagulation factors, carotid 
      intima-media thickness and endothelial dysfunction. New insights of acarbose 
      therapy obtained like increased activity of gut hormones and improved gut 
      microbiota may explain the benefits on weight, whereas increased production of H2 
      may explains its cardiovascular benefits to some extent. AREAS COVERED: A 
      systematic search strategy was developed to identify randomized controlled trials 
      in MEDLINE, PubMed, EMBASE and ongoing trials databases. EXPERT OPINION: AGIs as 
      a class and acarbose in particular, are most useful in combatting PPHG and 
      glucose variability across the spectrum of diabetes therapy, particularly in 
      Asian patients. Together with their effects on incretin hormones and 
      gut-microbiota AGIs can be considered beyond glycemic control as 
      'cardio-protective agents.'
FAU - Joshi, Shashank R
AU  - Joshi SR
AD  - Joshi Clinic, Bandra West , Mumbai, Maharashtra , India shashank.sr@gmail.com.
FAU - Standl, Eberhard
AU  - Standl E
FAU - Tong, Nanwei
AU  - Tong N
FAU - Shah, Parag
AU  - Shah P
FAU - Kalra, Sanjay
AU  - Kalra S
FAU - Rathod, Rahul
AU  - Rathod R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Glycoside Hydrolase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - T58MSI464G (Acarbose)
SB  - IM
MH  - Acarbose/therapeutic use
MH  - Blood Glucose/analysis
MH  - Cardiovascular Diseases/etiology/pathology/prevention & control
MH  - Carotid Intima-Media Thickness
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Glycoside Hydrolase Inhibitors/*therapeutic use
MH  - Humans
MH  - Hyperglycemia/*drug therapy
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/therapeutic use
OTO - NOTNLM
OT  - acarbose
OT  - cardiovascular disease
OT  - diabetes mellitus
OT  - miglitol
OT  - postprandial hyperglycemia
OT  - type 2
OT  - voglibose
OT  - alpha-glucosidase inhibitors
EDAT- 2015/08/11 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/08/11 06:00
PHST- 2015/08/11 06:00 [entrez]
PHST- 2015/08/11 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1517/14656566.2015.1070827 [pii]
AID - 10.1517/14656566.2015.1070827 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2015;16(13):1959-81. doi: 
      10.1517/14656566.2015.1070827.